Citations

Institution: Mayo Clinic Clear

Showing 10 of 108104 citations.

Phase I Study of a Modified Regimen of 90 Yttrium–Ibritumomab Tiuxetan for Relapsed or Refractory Follicular or Transformed CD20+ Non-Hodgkin Lymphoma
Meredith, Ruby F. , Shen, Sui , Knox, Susan J., Micallef, Ivana N. , Shah, Jatin J., LoBuglio, Albert F., Forero‐Torres, Andres , Vaklavas, Christos

Cancer Biotherapy and Radiopharmaceuticals | March 26, 2013 | Volume: 28 | Issue: 5 | Pages: 370-379

10.1089/cbr.2012.1387 | PMID 23530878 Get It

Immunosuppression by Co‐stimulatory Molecules: Inhibition of CD2‐CD48/CD58 Interaction by Peptides from CD2 to Suppress Progression of Collagen‐induced Arthritis in Mice
Gokhale, Ameya, Kanthala, Shanthi, Latendresse, John R., Taneja, Veena , Satyanarayanajois, Seetharama D., Taneja, Veena

Chemical Biology & Drug Design | March 26, 2013 | Volume: 82 | Issue: 1 | Pages: 106-118

10.1111/cbdd.12138 | PMID 23530775 Get It

Targeting co‐stimulatory molecules to modulate the immune response has been shown to have useful therapeutic effects for autoimmune diseases. Among the co‐stimulatory molecules, CD2 and CD58 are very important in the early stages of generation of an immune response. Our goal was to utilize CD2‐derived peptides to modulate protein–protein interactions between CD2 and CD58, thereby modulating the immune response. Several peptides were designed based on the structure of the CD58‐binding domain of CD2 protein. Among the CD2‐derived peptides, peptide 6 from the F and C β‐strand region of CD2 protein exhibited inhibition of cell–cell adhesion in the nanomolar concentration range. Peptide 6 was evaluated for its ability to bind to CD58 in Caco‐2 cells and to CD48 in T cells from rodents. A molecular model was proposed for binding a peptide to CD58 and CD48 using docking studies. Furthermore, in vivo studies were carried out to evaluate the therapeutic ability of the peptide to modulate the immune response in the collagen‐induced arthritis (CIA) mouse model. In vivo studies indicated that peptide 6 was able to suppress the progression of CIA. Evaluation of the antigenicity of peptides in CIA and transgenic animal models indicated that this peptide is not immunogenic.
e-Professionalism: A New Frontier in Medical Education
Kaczmarczyk, J, Chuang, Alice, Dugoff, Lorraine , Abbott, Jodi , Cullimore, Amie J., Dalrymple, John L. , Davis, Katrina, Hueppchen, Nancy A. , Katz, Nadine T. , Nuthalapaty, Francis S., Pradhan, Archana , Wolf, Abigail , Casey, Petra M.

Teaching and Learning in Medicine | March 26, 2013 | Volume: 25 | Issue: 2 | Pages: 165-170

10.1080/10401334.2013.770741 | PMID 23530680 Get It

Transoral laser microsurgery followed by radiation therapy for oropharyngeal tumors: The mayo clinic arizona experience
Patel, Samir H. , Hinni, Michael L., Hayden, Richard E. , Wong, William W. , Dueck, Amylou C. , Zarka, Matthew A., Curtis, Kelly K., Halyard, Michele Y. , Dueck, A. C.

Head & Neck | March 26, 2013 | Volume: 36 | Issue: 2 | Pages: 220-225

10.1002/hed.23279 | PMID 23529906 Get It

BackgroundThe purpose of this study was to report the treatment outcomes of patients with advanced oropharyngeal cancer treated with transoral laser microsurgery (TLM) followed by radiation therapy (RT) at Mayo Clinic in Arizona.MethodsA retrospective study of 80 patients treated from January 1, 2000 to November 7, 2011 was performed. All patients had stage III/IV oropharyngeal tumors and underwent TLM with neck dissection. Adjuvant RT was then given. Thirty‐seven patients received concurrent adjuvant chemotherapy. The primary outcome was locoregional control.ResultsMedian follow‐up was 47.3 months (range, 9.7–139.2 months). The 3‐year locoregional control, recurrence‐free survival, and overall survival rates were 98.6% (95% confidence interval [CI], 91% to 100%), 91.1% (95% CI, 81% to 96%), and 93.7% (95% CI, 84% to 98%), respectively. There were a total of 5 treatment failures, 1 regional and 4 distant. Twenty‐six patients underwent neck only RT with exclusion of the primary site.ConclusionTLM followed by RT for advanced oropharyngeal cancer results in excellent locoregional control rates. © 2013 Wiley Periodicals, Inc. Head Neck 36: 220–225, 2014
Effect of Prior Radiotherapy and Ablative Therapy on Surgical Outcomes for the Treatment of Rectourethral Fistulas
Linder, Brian J. , Umbreit, Eric , Dozois, Eric J. , Thapa, Prabin , Elliott, Daniel S. , Larson, David W. , Linder, Brian J

Journal of Urology | March 26, 2013 | Volume: 190 | Issue: 4 | Pages: 1287-1291

10.1016/j.juro.2013.03.077 | PMID 23538238 Get It

Neuroradiological evaluation of demyelinating disease
Tillema, Jan‐Mendelt , Pirko, Istvan

Therapeutic Advances in Neurological Disorders | March 26, 2013 | Volume: 6 | Issue: 4 | Pages: 249-268

10.1177/1756285613478870 | PMID 23858328 Get It

Central nervous system inflammatory demyelinating disease can affect patients across the life span. Consensus definitions and criteria of all of the different acquired demyelinating diseases that fall on this spectrum have magnetic resonance imaging criteria. The advances of both neuroimaging techniques and important discoveries in immunology have produced an improved understanding of these conditions and classification. Neuroimaging plays a central role in the accurate diagnosis, prognosis, disease monitoring and research efforts that are being undertaken in this disease. This review focuses on the imaging spectrum of acquired demyelinating disease.
Podocyturia Predates Proteinuria and Clinical Features of Preeclampsia
Craici, Iasmina , Wagner, Steven J., Bailey, Kent R. , Fitz‐Gibbon, Patrick D., Wood‐Wentz, Christina M. , Hayman, Suzanne R. , Brost, Brian , Rose, Carl H., Grande, Joseph P. , Garovic, Vesna D. , Turner, Stephen T. , White, Wendy , Garovic, Vesna D

Hypertension | March 26, 2013 | Volume: 61 | Issue: 6 | Pages: 1289-1296

10.1161/hypertensionaha.113.01115 | PMID 23529165 Get It

Podocyturia, the shedding of live podocytes, is present at delivery in women with preeclampsia. The aim of this study was to test whether podocyturia is present earlier in pregnancy and predicts for preeclampsia. We also aimed to compare test characteristics of podocyturia with those of angiogenic factors previously implicated in the pathogenesis of this disorder. We prospectively enrolled 315 women who provided blood and urine samples at the end of the second trimesters of their pregnancies (median, 27 gestational weeks) and within 24 hours of their deliveries (median, 39.5 gestational weeks). Blood samples were analyzed for angiogenic markers, including placental growth factor, the soluble receptor fms-like tyrosine kinase receptor-1 for vascular endothelial growth factor, and endoglin. The urine sediments were analyzed for podocytes, identified by staining for podocin after culturing the urinary sediments for 24 hours. This analysis included all women who developed preeclampsia (n=15), gestational hypertension (n=15), and a subsample of women who remained normotensive throughout pregnancy (n=44), matched for maternal age and number of previous pregnancies to those who developed preeclampsia. At the second trimester collection, all women who developed preeclampsia had podocyturia, compared with none of those who remained normotensive or were diagnosed with gestational hypertension. Podocyturia in the second trimester had a significantly greater sensitivity and specificity for the subsequent diagnosis of preeclampsia than any single angiogenic marker or a combination thereof. Screening for podocyturia at the end of the second trimester may allow for accurate identification of pregnant women at risk for preeclampsia.
Review of Aflibercept for the Treatment of Neovascular Age-Related Macular Degeneration
Stewart, Michael W.

Clinical Medicine Insights: Therapeutics | March 25, 2013 | Volume: 5 | Issue: No issue available | Pages: No page available

10.4137/cmt.s8921 Get It

The treatment of exudative age-related macular degeneration (AMD) has been completely transformed by the development of drugs that bind vascular endothelial growth factor (VEGF). The antibody-based VEGF inhibitors bevacizumab and ranibizumab usually prevent the enlargement of choroidal neovascular membranes, reduce vascular permeability, and improve visual acuity. The newest VEGF inhibitor, aflibercept, is a soluble fusion protein that binds all isoforms of VEGF-A, VEGF-B, and placental growth factor with high affinity. Preclinical studies demonstrated aflibercept's ability to prevent experimental neovascularization and tumor growth in animal models. In phase 3 trials for exudative AMD, patients who received aflibercept avoided moderate vision loss and experienced improved visual acuity comparable to those who received ranibizumab. Additionally, patients who were treated with aflibercept 2 mg every 8 weeks (after 3 monthly loading doses) had similar visual results to those treated every 4 weeks. When treated as needed during the second year of the trials, patients were able to last an average of 3 months between aflibercept injections. Since its regulatory approval, aflibercept has also been found to perform well as a salvage therapy for eyes that respond incompletely to ranibizumab and bevacizumab. Because aflibercept can be administered less frequently than ranibizumab, it promises to decrease the frequency of patients’ visits to physicians’ offices in addition to the overall cost of AMD therapy.
Response to Letter Regarding Article, “Incidence of Infective Endocarditis due to Viridans Group Streptococci Before and After Publication of the 2007 American Heart Association’s Endocarditis Prevention Guidelines”
Tleyjeh, Imad M. , de, Daniel D. Correa, Anavekar, Nandan S., Lahr, Brian D. , Sohail, M. Rizwan , Steckelberg, James M., Wilson, Walter R. , DeSimone, Daniel C. , Baddour, Larry M. , Sohail, M Rizwan , Tleyjeh, Imad M

Circulation | March 25, 2013 | Volume: 127 | Issue: 12 | Pages: No page available

10.1161/circulationaha.112.147553 | PMID 23646371 Get It

Neuropathic midfoot deformity: associations with ankle and subtalar joint motion
Sinacore, David R. , Gutekunst, David J. , Hastings, Mary K. , Strube, Michael , Bohnert, Kathryn L. , Prior, Fred , Johnson, Jeffrey E.

Journal of Foot and Ankle Research | March 25, 2013 | Volume: 6 | Issue: 1 | Pages: No page available

10.1186/1757-1146-6-11 | PMID 23531372 Get It

AbstractBackgroundNeuropathic deformities impair foot and ankle joint mobility, often leading to abnormal stresses and impact forces. The purpose of our study was to determine differences in radiographic measures of hind foot alignment and ankle joint and subtalar joint motion in participants with and without neuropathic midfoot deformities and to determine the relationships between radiographic measures of hind foot alignment to ankle and subtalar joint motion in participants with and without neuropathic midfoot deformities.MethodsSixty participants were studied in three groups. Forty participants had diabetes mellitus (DM) and peripheral neuropathy (PN) with 20 participants having neuropathic midfoot deformity due to Charcot neuroarthropathy (CN), while 20 participants did not have deformity. Participants with diabetes and neuropathy with and without deformity were compared to 20 young control participants without DM, PN or deformity. Talar declination and calcaneal inclination angles were assessed on lateral view weight bearing radiograph. Ankle dorsiflexion, plantar flexion and subtalar inversion and eversion were assessed by goniometry.ResultsTalar declination angle averaged 34±9, 26±4 and 23±3 degrees in participants with deformity, without deformity and young control participants, respectively (p< 0.010). Calcaneal inclination angle averaged 11±10, 18±9 and 21±4 degrees, respectively (p< 0.010). Ankle plantar flexion motion averaged 23±11, 38±10 and 47±7 degrees (p<0.010). The association between talar declination and calcaneal inclination angles with ankle plantar flexion range of motion is strongest in participants with neuropathic midfoot deformity. Participants with talonavicular and calcaneocuboid dislocations result in the most severe restrictions in ankle joint plantar flexion and subtalar joint inversion motions.ConclusionsAn increasing talar declination angle and decreasing calcaneal inclination angle is associated with decreases in ankle joint plantar flexion motion in individuals with neuropathic midfoot deformity due to CN that may contribute to excessive stresses and ultimately plantar ulceration of the midfoot.